|4.||Liver Diseases (Liver Disease)
|1.||Lai, Ching-Lung: 86 articles (09/2015 - 02/2002)|
|2.||Yuen, Man-Fung: 68 articles (09/2015 - 02/2002)|
|3.||Marcellin, Patrick: 67 articles (01/2016 - 01/2002)|
|4.||Janssen, Harry L A: 64 articles (08/2015 - 10/2003)|
|5.||Kao, Jia-Horng: 59 articles (12/2015 - 01/2002)|
|6.||Kumada, Hiromitsu: 55 articles (01/2015 - 01/2002)|
|7.||Liaw, Yun-Fan: 53 articles (08/2015 - 01/2002)|
|8.||Zoulim, Fabien: 51 articles (10/2015 - 01/2002)|
|9.||Suzuki, Fumitaka: 47 articles (01/2015 - 01/2002)|
|10.||Han, Kwang-Hyub: 44 articles (11/2015 - 12/2002)|
|1.||Lamivudine (3TC)FDA Link
01/01/2002 - "However, durable posttreatment remission of chronic hepatitis B has not been shown to occur in a significant number of lamivudine-treated patients. "
07/01/2001 - "A long-term follow-up study was carried out to evaluate the tolerability and efficacy of long-term therapy (1 to 3 years) with high doses (150 or 300 mg daily) of lamivudine for chronic hepatitis B. "
04/01/2009 - "Anti-HBV therapeutic trials in Asia have shown that AE of chronic hepatitis B (CH-B) may result in increased sustained remission (SR) rate with lamivudine monotherapy. "
06/01/2007 - "The aim of this study was to compare the efficacy of lamivudine therapy between chronic hepatitis B (CHB) patients, whose ALT levels less than 2 times the upper limit of normal (ULN) and patients whose ALT levels are more than 2 times ULN. "
04/01/2005 - "The major aim of our study was the assessment of the efficacy of lamivudine therapy in children with chronic hepatitis B (CHB). "
|2.||Hepatitis B e AntigensIBA
01/01/2009 - "Responses in HBeAg-negative chronic hepatitis B were very high during treatment but high relapse rates eliminated most of the long-time treatment effect. "
02/01/2013 - "In HBeAg-negative genotype D patients with chronic hepatitis B, PegIFN treatment for 96 weeks was well tolerated and the post-treatment virological response improved significantly compared with 48 weeks of treatment. "
01/01/2009 - "In conclusion, peginterferon-alpha-2a (40 kD) is a valuable option for the first-line treatment of HBeAg-negative or -positive chronic hepatitis B."
06/01/2007 - "This observation may help to develop better clinical management in HBeAg-negative chronic hepatitis B patients."
01/01/2009 - "These findings suggest that 9 microg CIFN is effective in the treatment of patients with HBeAg-positive chronic hepatitis B. "
11/14/2014 - "Several clinical trials have demonstrated the potent antiviral efficacy of entecavir (ETV), and this relatively new nucleoside analogue drug has rapidly become a frequently prescribed therapy for chronic hepatitis B (CHB) worldwide. "
11/01/2013 - "Entecavir (Baraclude®, Bristol-Myers Squibb) is a potent and selective antiviral agent that has demonstrated efficacy in patients with chronic hepatitis B. "
04/01/2010 - "To assess therapeutic efficacy in this clinical setting, we retrospectively examined treatment endpoints among the subset of nucleoside-naïve chronic hepatitis B (CHB) patients treated in phase 3 clinical trials of entecavir who had both screening and baseline serum ALT 1.3 to 2 x ULN. "
05/01/2012 - "Entecavir is an effective treatment for chronic hepatitis B. "
03/01/2011 - "Long-term treatment with entecavir resulted in durable virologic suppression and continued histologic improvement in nucleoside-naive chronic hepatitis B patients. "
|4.||Interferon-alpha (Interferon Alfa)FDA Link
05/01/1998 - "Since interferon alpha administration has proven effective in chronic hepatitis-B therapy, we decided to administer interferon alpha 2a (13,46,47,55). "
09/01/2008 - "Interferon-alpha treatment tailored in length demonstrated significantly increased efficacy in patients with chronic hepatitis B."
09/01/2000 - "The only agent known to have a lasting beneficial effect in chronic hepatitis B is interferon alpha, which achieves long-term remission in 25-40% of the patients. "
11/01/1999 - "Efficacy of high dose interferon--alpha treatment of chronic hepatitis B."
11/01/1998 - "Alpha-interferon (IFN-alpha) is an effective treatment for chronic hepatitis B but only 25-40% of patients will profit from a long-term beneficial response to the currently recommended schedule of 3-6 MU given 3 times a week for 6 months. "
08/01/2012 - "However, in striking contrast to the situation in chronic hepatitis B and C, no new drugs for its treatment have been introduced in the recent past and interferons remain the only evidence-based effective treatment of CDH. "
12/14/2007 - "The treatment of chronic hepatitis B has improved dramatically over the last decade merits to the advent of nucleoside/nucleotide analogues and the use of pegylated interferons. "
01/01/2006 - "The treatment of chronic hepatitis B has improved dramatically over the last decade thanks to the advent of nucleoside/nucleotide analogues and the use of pegylated interferons. "
09/01/1994 - "Interferon is the sole drug yet proven to be effective in the treatment of some patients with chronic hepatitis B and C. "
05/01/1999 - "Chronic hepatitis B treatment has been significantly improved by interferon (IFN) treatment. "
09/01/2011 - "Hepatitis B virus (HBV) core antigen-specific regulatory T cells confer sustained remission to anti-HBV therapy in chronic hepatitis B with acute exacerbation."
11/01/2009 - "Our study was carried out in 215 HBs antigen positive patients, including 176 asymptomatic carriers originated from regions of variable hepatitis B virus (HBV) endemicities, and 39 hepatitis B chronic patients with delta positive serology. "
10/01/2009 - "127 adult e antigen-negative chronic hepatitis B patients were enrolled in this study. "
01/01/2008 - "A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients."
06/01/2005 - "The aim of the study was an evaluation of the somatic development of children with chronic hepatitis B, C and HBs antigen positive and finding the correlation between the nutrition status, the duration of disease and the aminotransferase activity. "
|7.||DNA (Deoxyribonucleic Acid)IBA
12/01/1996 - "The measurement of hepatitis B virus (HBV) DNA, is important for monitoring and evaluating the efficacy of anti-viral agents in the treatment of patients with chronic hepatitis B. "
06/01/2013 - "The combination regimen is a promising approach to treat chronic hepatitis B and may achieve significant reduction in serum HBV DNA and intrahepatic cccDNA. "
09/01/2004 - "The diagnosis of chronic hepatitis B, based on HBV DNA positive results, was more frequent in HIV-positive women (26.7%), compared to HIV-negative women (9.4%) (P = 0.06). "
07/01/1995 - "We conclude that the seroconversion to anti-HBe accompanied by disappearance of serum HBV DNA even by PCR does not necessarily suggest a sustained remission of chronic hepatitis B."
12/31/2008 - "In this study, we assessed the utility of EP as a tool to improve the efficacy of HB-110, a novel therapeutic DNA vaccine against chronic hepatitis B, now in phase 1 of clinical study in South Korea. "
|8.||adefovir dipivoxil (Hepsera)FDA Link
01/01/2012 - "Adefovir dipivoxil (ADV) is a nucleotide analogue with proven efficacy in chronic hepatitis B (CHB). "
01/01/2003 - "Existing treatment options for patients with chronic hepatitis B are limited in both number and effectiveness; the proven efficacy, good tolerability profile and apparently low potential for resistance of adefovir dipivoxil make it a promising new option in the management of this disease."
01/01/2012 - "We developed an improved reverse dot hybridization test for simple and rapid detection of the rtA181V/T and rtN236T mutations associated with adefovir dipivoxil resistance in chronic hepatitis B patients. "
03/01/2004 - "Adefovir dipivoxil, a nucleotide analogue recently approved by the Food and Drug Administration for the treatment of chronic hepatitis B, is effective against hepatitis B virus (HBV) but has been associated with renal toxicity at high doses. "
11/01/2004 - "Effective phosphorylation coupled with a long intracellular half-life and small competing dATP pool sizes in primary hepatocytes forms the cellular metabolic basis for the efficacy of adefovir dipivoxil in the treatment of chronic hepatitis B."
02/01/2013 - "Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poor virological response to peginterferon alfa."
01/01/2004 - "Adefovir 10 mg/d orally is safe and effective for treatment of chronic hepatitis B."
04/01/2013 - "Chronic hepatitis B clinic patients from a tertiary hospital on adefovir treatment, with their clinical and laboratory parameters were extracted from the hospital electronic clinical database in an observational study design. "
05/01/2008 - "The aims of the present study were to assess initial virological response (IVR) to adefovir (ADV) treatment for chronic hepatitis B, to identify patients with suboptimal response and to determine the incidence of ADV-resistant mutants. "
02/21/2015 - "Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B."
|10.||Hepatitis B Surface Antigens (HBsAg)FDA Link
06/01/2014 - "During the natural course of chronic hepatitis B, changes or absolute level of sAg less than certain level can predict spontaneous sero-clearance of HBsAg. "
08/01/2013 - "Clearance of hepatitis B surface antigen (HBsAg) is considered the ultimate goal in chronic hepatitis B treatment. "
08/01/2013 - "Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study."
01/01/2012 - "Among fifty-eight sera, ELISA showed fifty-five (94.8%) of the samples were positive for HBsAg and three (5.2%) negative results obtained while real-time PCR specified fifty-eight (100%) positive results in chronic hepatitis B patients. "
12/01/2010 - " Specimens collected from 43 cases of chronic hepatitis B patients with positive results for both HBsAg and HBsAb tests were used as the experimental group; specimens collected from 43 cases randomly picked from all patients with chronic hepatitis B with a single positive result for HBsAg test were used as the control group. "
09/01/2000 - "Twenty-five patients with chronic hepatitis B after liver transplantation were included in this study. "
11/14/2015 - "In the absence of prophylaxis, liver transplantation due to chronic hepatitis B (CHB) is associated with high rates of viral recurrence and poor survival. "
09/01/2013 - "In patients infected with chronic hepatitis B virus (HBV) that goes untreated, therapeutic options are limited once the disease decompensates, and orthotopic liver transplantation is often the only treatment available to save the patient's life. "
01/01/2013 - "Severe acute exacerbation in chronic hepatitis B could lead to mortality in some patients unless timely liver transplantation is performed. "
10/01/2011 - "Decompensated chronic hepatitis B cirrhotics may suffer early mortality despite antiviral treatment, and therefore should be considered for early liver transplantation."
01/01/2003 - "[Histopathological improvement in chronic hepatitis B patients after treatment of marin solution]."
11/08/2011 - "Serum levels of sCD26 and sCD30, before, 1 and 3 months after treatment commencement were evaluated in 53 chronic hepatitis B patients and 30 healthy individuals as control group. "
05/01/2008 - "Treatment of chronic hepatitis B is often complicated by the appearance of escape mutants after treatment with nucleoside analogs, especially with genotypes responsible for the more severe form of the disease. "
04/01/1999 - "What once was lost, now is found: restoration of hepatitis B-specific immunity after treatment of chronic hepatitis B."
08/01/2014 - "Registration studies show entecavir (ETV) to be effective and safe in NUC-naïve patients with chronic hepatitis B, but relapse rates after treatment discontinuation have not been well established. "
|3.||Transplantation (Transplant Recipients)
06/01/2013 - "We aimed to determine the long-term outcomes from a large population of chronic hepatitis B (CHB) liver transplant recipients using oral antiviral therapy alone. "
01/01/2012 - "A novel experience of antiviral therapy for chronic hepatitis B in renal transplant recipients."
05/01/2009 - "Emergency transplantation for acute reactivation of chronic hepatitis B with high viral load: role of antiviral therapy."
04/01/2007 - "Treatment of chronic hepatitis B in renal transplant recipients remains one of the major problems in clinical nephrology. "
11/01/2006 - "A high prevalence of chronic hepatitis B has been previously reported in heart transplant recipients in our center. "
|4.||Chinese Traditional Medicine (Traditional Chinese Medicine)
01/01/2013 - "Traditional Chinese medicine (TCM) treatment is regarded as a safe and effective method for chronic hepatitis B (CHB), which requires a traditional diagnosis method to distinguish the TCM syndrome. "
10/01/2009 - "To study the phenotypes and functions of dendritic cells (DCs) derived from peripheral blood monocytes of chronic hepatitis B (CHB) patients with different traditional Chinese medicine (TCM) syndrome types, and to explore the relationship between TCM syndrome type and DC functions. "
12/01/2007 - "[Advances in studies on effect superiorities of traditional Chinese medicine on chronic hepatitis B]."
10/15/2006 - "To study the clinical outcome of traditional Chinese medicine-induced hepatotoxicity in chronic hepatitis B patients. "
10/01/1985 - "[Preliminary clinical study of the effect of complex traditional Chinese medicine pills (848) on chronic hepatitis B virus carriers]."
12/01/2015 - "To assess a new adenovirus-based immunotherapy as a novel treatment approach to chronic hepatitis B (CHB). "
10/01/2012 - "[Progress in immunotherapy for chronic hepatitis B]."
01/01/2010 - "This information may be useful for designing immunotherapies for chronic hepatitis B. "
12/01/2005 - "Weak therapeutic responses and weak immune cytotoxic CD8 and CD4 response in chronic hepatitis B emphasize the necessity to find new therapeutic strategies especially as specific immunotherapy. "
02/01/2003 - "This review summarizes the immune response in acute, self-limited and chronic hepatitis B; its differential effects on viral replication and liver injury; and prospects for immunotherapy."